<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00997750</url>
  </required_header>
  <id_info>
    <org_study_id>AB-CCH-51</org_study_id>
    <nct_id>NCT00997750</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lornoxicam in Patients With Acute Coronary Syndrome</brief_title>
  <acronym>PLEA</acronym>
  <official_title>Prospective Randomized Double-center Study of Nonsteroidal Antinflammatory Drug Lornoxicam in Patients With Acute Coronary Syndrome Without Persistent ST- Segment Elevation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether nonsteroidal antiinflammatory drug
      lornoxicam in combination with low dose aspirin (100mg/day) is effective and safe in patients
      with Acute Coronary Syndrome without persistent ST-segment elevation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nonsteroidal Antiinflammatory drugs (NSAIDs) are the most frequently prescribed drugs in the
      world. There are a lot of controversial information published during recent years about NSAID
      cardiosafety. It is still unclear do NSAIDs develop cardioprotective or cardiotoxic effects
      in acute and chronic heart disease patients. Aim of the study was to investigate safety and
      efficacy of Lornoxicam, nonselective COX-inhibitor, in patients with acute coronary syndrome
      without ST-segment elevation (NSTEACS) and to evaluate the influence of Lornoxicam on
      C-reactive protein (CRP) and IL-6, IL-10 levels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All Cardiovascular events (cardiovascular dearth+nonfatal miocardial infarction+unstable angina)</measure>
    <time_frame>six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Noncardiovascular death, Gastrointestinal bleeding</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Lornoxicam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lornoxicam 8mg/day and 12mg/day for 15 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lornoxicam</intervention_name>
    <description>lornoxicam 8mg/day and 12mg/day for 15 days</description>
    <arm_group_label>Lornoxicam</arm_group_label>
    <other_name>Xefocam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Unstable angina verified during first 48 hours after admitting to the hospital or

          2. Acute Miocardial infarction without St-segment elevation verified during first 48
             hours after admitting to the hospital

        Exclusion Criteria:

          1. High risk of bleeding of any location

          2. Any kind of acute and active inflammatory process (excluding acute coronary syndrome)

          3. Aspirin or NSAID Intolerability

          4. No informed consent

          5. Acute peptic stomach or duodenum ulcer

          6. Acute or chronic renal failure (serum creatinin &gt;300 mmol/l)

          7. Acute cerebrovascular bleeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexei K Gruzdev, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardiology, Central Clinical Hospital of Presidential Administration of Russian Federation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Clinical Hospital of Presidential Department Of Russian Federation</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <reference>
    <citation>Lomakin N.V., Gruzdev A.K. Cardiovascular risks of cyclooxygenase inhibitors (data review). Kardiol serdecno-sosud hir #1:28-36, 2009 (http://www.mediasphera.ru/journals/cardsurg/530/eng/8095/)</citation>
  </reference>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2009</study_first_submitted>
  <study_first_submitted_qc>October 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2009</study_first_posted>
  <last_update_submitted>October 18, 2009</last_update_submitted>
  <last_update_submitted_qc>October 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr Nikita Lomakin</name_title>
    <organization>Central Clinical Hospital of President Department of Russian Federation</organization>
  </responsible_party>
  <keyword>ACS</keyword>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>NSAID</keyword>
  <keyword>Lornoxicam</keyword>
  <keyword>Xefocam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lornoxicam</mesh_term>
    <mesh_term>Piroxicam</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 11, 2011</submitted>
    <submission_canceled>Unknown</submission_canceled>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

